$80.85 Million in Sales Expected for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) This Quarter

Brokerages predict that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) will announce sales of $80.85 million for the current quarter, Zacks reports. Two analysts have provided estimates for Harmony Biosciences’ earnings, with the lowest sales estimate coming in at $77.40 million and the highest estimate coming in at $84.30 million. Harmony Biosciences reported sales of $45.61 million during the same quarter last year, which indicates a positive year over year growth rate of 77.3%. The firm is expected to issue its next earnings results on Thursday, November 11th.

According to Zacks, analysts expect that Harmony Biosciences will report full year sales of $306.85 million for the current financial year, with estimates ranging from $298.10 million to $315.60 million. For the next year, analysts forecast that the firm will post sales of $513.60 million, with estimates ranging from $440.90 million to $586.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Harmony Biosciences.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Monday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.06. Harmony Biosciences had a net margin of 9.86% and a return on equity of 66.92%. The business had revenue of $73.82 million for the quarter, compared to analyst estimates of $70.85 million.

Separately, Zacks Investment Research raised shares of Harmony Biosciences from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a report on Wednesday, August 11th.

In related news, CEO John C. Jacobs sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, September 13th. The shares were sold at an average price of $35.93, for a total transaction of $898,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeffrey M. Dayno sold 2,159 shares of the stock in a transaction on Thursday, August 26th. The stock was sold at an average price of $35.01, for a total transaction of $75,586.59. Following the completion of the sale, the insider now directly owns 1,600 shares of the company’s stock, valued at approximately $56,016. The disclosure for this sale can be found here. In the last three months, insiders sold 42,159 shares of company stock valued at $1,460,926. Company insiders own 28.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in shares of Harmony Biosciences by 5.4% in the first quarter. Janus Henderson Group PLC now owns 1,153,783 shares of the company’s stock valued at $38,120,000 after purchasing an additional 59,334 shares during the period. Nuveen Asset Management LLC lifted its position in shares of Harmony Biosciences by 449.0% in the 1st quarter. Nuveen Asset Management LLC now owns 55,764 shares of the company’s stock worth $1,842,000 after buying an additional 45,607 shares during the last quarter. Polaris Capital Management LLC bought a new position in shares of Harmony Biosciences in the 2nd quarter worth about $872,000. Virtus ETF Advisers LLC lifted its position in shares of Harmony Biosciences by 2.8% in the 1st quarter. Virtus ETF Advisers LLC now owns 15,322 shares of the company’s stock worth $506,000 after buying an additional 423 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Harmony Biosciences by 237.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company’s stock worth $49,000 after buying an additional 1,233 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

HRMY stock traded down $0.23 during trading on Friday, reaching $36.56. 5,989 shares of the company were exchanged, compared to its average volume of 228,571. The company has a market cap of $2.08 billion and a P/E ratio of 159.96. Harmony Biosciences has a 52-week low of $25.09 and a 52-week high of $52.74. The stock’s 50 day moving average price is $31.66 and its 200 day moving average price is $30.70. The company has a debt-to-equity ratio of 1.55, a quick ratio of 5.46 and a current ratio of 5.59.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States.

Further Reading: Institutional Investors

Get a free copy of the Zacks research report on Harmony Biosciences (HRMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.